Patients’ medication by room type
| Treatment | Room without radiant cooling % | Room with radiant cooling % | p-value |
| LABA, n (%) | 12 (60) | 33 (79) | 0.205 |
| LAMA, n (%) | 13 (65) | 28 (67) | 0.892 |
| SABA, n (%) | 8 (40) | 26 (62) | 0.149 |
| SAMA, n (%) | 5 (25) | 11 (26) | 0.992 |
| ICS, n (%) | 9 (45) | 27 (64) | 0.213 |
| Systemic corticosteroid, n (%) | 12 (60) | 15 (36) | 0.046* |
| Methylxanthine, n (%) | 1 (5.0) | 11 (26) | 0.057 |
| Leukotriene antagonist, n (%) | 0 (0.0) | 2 (4.8) | 0.333 |
| Angiotensin-II-receptor antagonist, n (%) | 1 (5.0) | 7 (17) | 0.222 |
| ACE inhibitor, n (%) | 12 (60) | 8 (19) | 0.001** |
| Beta blocker | 7 (35) | 13 (31) | 0.650 |
| Diuretic | 9 (45) | 20 (48) | 0.986 |
Comparisons were made by chi-squared test. LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist; SABA: short-acting beta2-agonist; SAMA: short-acting muscarinic antagonist; ICS: inhaled corticosteroid; ACE: angiotensin-converting enzyme. * p<0.05; ** p<0.01.